1. Home
  2. HYPR vs IFRX Comparison

HYPR vs IFRX Comparison

Compare HYPR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

N/A

Current Price

$1.18

Market Cap

107.9M

Sector

Health Care

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$0.96

Market Cap

60.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYPR
IFRX
Founded
2014
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.9M
60.6M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
HYPR
IFRX
Price
$1.18
$0.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$1.28
$8.50
AVG Volume (30 Days)
291.7K
178.8K
Earning Date
04-20-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
9.68
N/A
EPS
N/A
N/A
Revenue
$12,890,000.00
N/A
Revenue This Year
$5.96
N/A
Revenue Next Year
$34.43
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
16.84
N/A
52 Week Low
$0.53
$0.71
52 Week High
$2.22
$1.94

Technical Indicators

Market Signals
Indicator
HYPR
IFRX
Relative Strength Index (RSI) 55.14 56.15
Support Level $1.04 $0.96
Resistance Level $1.19 $1.16
Average True Range (ATR) 0.07 0.06
MACD 0.01 0.01
Stochastic Oscillator 68.29 82.45

Price Performance

Historical Comparison
HYPR
IFRX

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: